BACKGROUND
Biologics are generally reserved for severe asthma (SA) after standard treatments have failed. Their recommendation is based on randomized controlled trials, designed to assess efficacy but not the optimal timing for biologic initiation.
RESEARCH QUESTION
Does the timing of biologic initiation affect SA ou...
G. Canonica, G. Christoff, Ming-Ju Tsai et al.· Chest· 0 citations
This narrative review explores the evolving role of biomarkers across cardiovascular, renal, neurological, metabolic, metabolic, and respiratory diseases, focusing on their clinical and regulatory contexts of use-diagnostic, prognostic, predictive, surrogate, safety, and pharmacodynamic/response.
Achilleas Livieratos, Laura Goea, V. Das et al.· Therapeutic Innovation and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.